Gangliosides in Cancer Cell Signaling

Groux-Degroote, Sophie; Rodríguez-Walker, Macarena; Dewald, Justine H.; Daniotti, José L.; Delannoy, Philippe

doi:10.1016/bs.pmbts.2017.10.003

Cited by 56 publications

(49 citation statements)

References 172 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In response to siOGT, a significant upregulation by 25–30% of the neutral globoside GSLs was observed in the CRC cell lines, while similar tendency was observed in CCD841CoN cells (Figure B). The relative intensity of Gb3 was increased in the three cell lines and Gb4 increased in HCT116 only (Figure A) . In contrast, the proportion of gangliosides decreased in CCD841CoN and HCT116 cells (Figure C).…”

Section: Resultsmentioning

confidence: 92%

“…The relative intensity of Gb3 was increased in the three cell lines and Gb4 increased in HCT116 only ( Figure 4A). [30] In contrast, the proportion of gangliosides decreased in CCD841CoN and HCT116 cells ( Figure 4C). Beyond modifications in the glycan moiety of GSLs following silencing of OGT, we also observed differences in the acyl group for some glycolipids structures ( Figure 4A; Table S3, Supporting Information).…”

Section: Effect Of Ogt Silencing On Gsls Contentmentioning

confidence: 92%

See 1 more Smart Citation

OGT Controls the Expression and the Glycosylation of E‐cadherin, and Affects Glycosphingolipid Structures in Human Colon Cell Lines

et al. 2019

View full text Add to dashboard Cite

Colorectal cancer (CRC) affects both women and men living in societies with a high sedentary lifestyle. Amongst the phenotypic changes exhibited by tumor cells, a wide range of glycosylation has been reported for colon cancer‐derived cell lines and CRC tissues. These aberrant modifications affect different aspects of glycosylation, including an increase in core fucosylation and GlcNAc branching on N‐glycans, alteration of O‐glycans, upregulated sialylation, and O‐GlcNAcylation. Although O‐GlcNAcylation and complex glycosylations differ in many aspects, sparse evidences report on the interference of O‐GlcNAcylation with complex glycosylation. Nevertheless, this relationship is still a matter of debate. Combining different approaches on three human colon cell lines (HT29, HCT116 and CCD841CoN), it is herein reported that silencing O‐GlcNAc transferase (OGT, the sole enzyme driving O‐GlcNAcylation), only slightly affects overall N‐ and O‐glycosylation patterns. Interestingly, silencing of OGT in HT29 cells upregulates E‐cadherin (a major actor of epithelial‐to‐mesenchymal transition) and changes its glycosylation. On the other hand, OGT silencing perturbs biosynthesis of glycosphingolipids resulting in a decrease in gangliosides and an increase in globosides. Together, these results provide novel insights regarding the selective regulation of complex glycosylations by O‐GlcNAcylation in colon cancer cells.

show abstract

Section: Resultsmentioning

confidence: 92%

Section: Effect Of Ogt Silencing On Gsls Contentmentioning

confidence: 92%

OGT Controls the Expression and the Glycosylation of E‐cadherin, and Affects Glycosphingolipid Structures in Human Colon Cell Lines

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Antitumor therapy addressing these molecules has been gradually put into practice. 1019 N-Glycolylneuraminic acid is also a type of sialic acid, which deserves attention in tumor biology. 794 While Neu5Gc is almost completely absent from normal human tissues (only about 0.01% Neu5Gc of total sialic acid) (see Section 11.5.1), this value is often higher in tumor tissues, especially in their gangliosides (for example, 0.5% of total lipid-bound sialic acid).…”

Section: Sialic Acids In Tumorsmentioning

confidence: 99%

Exploration of the Sialic Acid World

Schauer

Kamerling

2018

Advances in Carbohydrate Chemistry and Biochemistry

250

225

View full text Add to dashboard Cite

The Sialic Acid World Table 1 Survey of Reported Structures of Naturally Occurring Members of the Sialic Acid Family-cont'd Name Abbreviation References5-N-Acetyl-8-O-acetyl-9-Olactyl-neuraminic acid Neu5,8Ac 2 9Lt 45 5-N-Acetyl-8-O-methylneuraminic acid Neu5Ac8Me 6,19,25,33,46 5-N-Acetyl-4-O-acetyl-8-Omethyl-neuraminic acid Neu4,5Ac 2 8Me 19 5-N-Acetyl-9-O-acetyl-8-Omethyl-neuraminic acid Neu5,9Ac 2 8Me 6,19,33,46 5-N-Acetyl-9-O-methylneuraminic acid Neu5Ac9Me 47 5-N-Acetyl-4-O-sulfoneuraminic acid Neu5Ac4S 48 5-N-Acetyl-8-O-sulfoneuraminic acid Neu5Ac8S 19,32,49,50 5-N-Acetyl-4-O-acetyl-8-Osulfo-neuraminic acid Neu4,5Ac 2 8S 19 5-N-Acetyl-9-O-phosphoneuraminic acid f,g Neu5Ac9P 51 5-N-Acetyl-2-deoxy-2,3didehydro-neuraminic acid g,h Neu2en5Ac 6,30,33,43,52-54 5-N-Acetyl-9-O-acetyl-2deoxy-2,3-didehydroneuraminic acid g Neu2en5,9Ac 2 55,56 5-N-Acetyl-2-deoxy-2,3didehydro-9-O-lactylneuraminic acid g Neu2en5Ac9Lt 55,565-N-Acetyl-2,7-anhydroneuraminic acid g,i

show abstract

“…Gangliosides (sialic-acid-containing glycosphingolipids) are important regulators of cell signalling in cancer [59]. The complex ganglioside GD2 is expressed on tumours of neuroectodermal origin and has a key role in the aggressiveness of some cancers including neuroblastoma and melanoma.…”

Section: Cancer-associated Sialyloglycansmentioning

confidence: 99%

Targeting Aberrant Sialylation to Treat Cancer

Munkley

Scott

2019

Medicines

View full text Add to dashboard Cite

Cell surface carbohydrates (known as glycans) are often aberrantly expressed or found at atypical levels in cancer. Glycans can impact all steps in tumour progression, from malignant transformation to metastasis, and have roles in all the cancer hallmarks. An increased understanding of glycans in the metastatic cascade offers exciting new therapeutic opportunities. Glycan-based targeting strategies are currently being tested in clinical trials and are a rich and untapped frontier for development. As we learn more about cancer glycobiology, new targets will continue to emerge for drug design. One key change in tumour glycosylation is the upregulation of cancer-associated sialylated glycans. Abnormal sialylation is integral to tumour growth, metastasis and immune evasion; therefore, targeting sialic acid moieties in cancer could be of high therapeutic value. Here, we summarise the changes to sialic acid biology in cancer and discuss recent advances and technologies bringing sialic-acid targeting treatments to the forefront of cancer therapeutics.

show abstract

Gangliosides in Cancer Cell Signaling

Cited by 56 publications

References 172 publications

OGT Controls the Expression and the Glycosylation of E‐cadherin, and Affects Glycosphingolipid Structures in Human Colon Cell Lines

OGT Controls the Expression and the Glycosylation of E‐cadherin, and Affects Glycosphingolipid Structures in Human Colon Cell Lines

Exploration of the Sialic Acid World

Targeting Aberrant Sialylation to Treat Cancer

Contact Info

Product

Resources

About